My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Viatris Inc. - Common Stock (NQ:VTRS)

15.77 -0.02 (-0.13%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Viatris Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

14 15 Next >

JP Morgan Shows Most Interest In Teva, Organon As Specialty Pharma Sector Exhibits Signs Of Stability ↗

September 06, 2024

JP Morgan assesses the specialty pharma sector, highlighting robust fundamentals and new product excitement. Key focus on Teva, Organon, and Viatris.

Via Benzinga

Shortage Relief: More Takeda's Vyvanse For ADHD On the Way As US Ramps Up Production ↗

September 06, 2024

Increase in production of Takeda's ADHD drug Vyvanse, approved by DEA to address ongoing shortages both domestically and globally.

Via Benzinga

3 Top Value Stocks to Buy Right Now ↗

August 20, 2024

Value stocks offer potential for significant returns in today's overheated market.

Via The Motley Fool

10 Health Care Stocks With Whale Alerts In Today's Session ↗

August 15, 2024

Via Benzinga

US Drugmaker Viatris Q2 Earnings Edge Out Analysts Expectation On Strong Demand For Branded And Generic Drugs ↗

August 08, 2024

Viatris reports Q2 revenue of $3.78 billion, with strong growth in Greater China and new product launches driving results. Adjusted EPS of $0.69 beats estimates, and the company raises its 2024 sales...

Via Benzinga

Peering Into Viatris's Recent Short Interest ↗

May 27, 2024

Via Benzinga

Looking Into Viatris's Recent Short Interest ↗

March 15, 2024

Via Benzinga

(VTRS) - Analyzing Viatris's Short Interest ↗

January 23, 2024

Via Benzinga

Why Viatris Stock Is Jumping Today ↗

August 08, 2024

Investors are applauding the healthcare company's improving growth story.

Via The Motley Fool

Novartis And Viatris Sued Over Unlawful Use Of HeLa Cells Used For Cancer Treatment Drugs ↗

August 06, 2024

Henrietta Lacks' family sues Novartis and Viatris for profiting from her HeLa cells without consent. The lawsuit seeks profits and aims to prevent further unauthorized use of the cells.

Via Benzinga

Topics Lawsuit

3 Surprisingly Underrated Stocks to Buy Right Now ↗

July 26, 2024

These stocks arguably deserve more respect from investors.

Via The Motley Fool

Warner Bros. Discovery & Coinbase Are Among 10 Large Cap Stocks That Shined Most Last Week (July 14-July 20): Are The Others In Your Portfolio? ↗

July 21, 2024

Top performers last week: $WBD up 18.28%, $MSTR up 16.74%, $DHI up 12.91%, $COIN up 12.39%, $OQL up 7.89%, $UNH up 7.84%, $STT up 7.21%, $LEN up 7.07%, $TOST up 7.05%, $EPAM up 6.97%. Are they in your...

Via Benzinga

S&P 500 Four Under Five ↗

June 28, 2024

The S&P 500's strong first half, with gains exceeding 15%, has pushed its valuation even higher.

Via Talk Markets

Topics Stocks

Weak Sales From Lipitor, Norvasc Hurt Viatris' Q1 Earnings, Lowers Annual Forecast ↗

May 09, 2024

Viatris reports Q1 EPS in line with consensus at $0.67, with sales slightly missing expectations at $3.66 billion. Strong growth in Emerging Markets and Europe offset by challenges in North America....

Via Benzinga

Stocks Rebound As Rising Jobless Claims Sustain Rate-Cut Hopes, Dollar Falls, Gold Rallies: What's Driving Markets Thursday? ↗

May 09, 2024

Wall Street is seeing a day of gains as all major indices traded in the green around noon in New York, driven by a surprising uptick in unemployment claims prompting speculation over Federal Reserve...

Via Benzinga

Topics Economy

VTRS Stock Earnings: Viatris Meets EPS, Misses Revenue for Q1 2024 ↗

May 09, 2024

VTRS stock results show that Viatris met analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.

Via InvestorPlace

BTIG Research Predicts Over 118% Rally for These 3 Stocks ↗

April 15, 2024

Wall Street stock predictions can run wild but after the tech sector's gains, these stocks could be better places for your money.

Via InvestorPlace

Steady Returns Ahead: 3 Dividend Stocks for Stable Income in Q2 ↗

April 03, 2024

Discover three top dividend stocks for stable income in April that combine sustainable returns and long-term growth.

Via InvestorPlace

Is Viatris a Great Dividend Stock or Just a Value Trap? ↗

March 14, 2024

Investors can collect a high yield with Viatris, but is it a risky payout to rely on?

Via The Motley Fool

2 Dirt Cheap Dividend Stocks to Buy and Hold ↗

March 11, 2024

These companies aren't popular on the market right now, but income investors will like them.

Via The Motley Fool

Stocks Fall Ahead Of Fed's Inflation Data, UnitedHealth Sinks, Bitcoin Tops $61,000: What's Driving Markets Wednesday? ↗

February 28, 2024

Stocks dipped modestly following a report indicating a marginal downward revision in the U.S. economic growth rate for the last quarter of the year.

Via Benzinga

Topics Economy

Viatris And Idorsia Forge Global Partnership For Breakthrough Heart Attack Treatments ↗

February 28, 2024

Viatris and Idorsia collaborate on groundbreaking heart attack treatments, leveraging innovative therapies for acute conditions.

Via Benzinga

3 Overextended Stocks That Need to Slash Their Dividends ASAP ↗

February 27, 2024

The most common attribute of overextended stocks other than carrying too much debt is dividends that are too big.

Via InvestorPlace

3 Bargain Stocks to Snatch Up Before They Bounce Back ↗

February 26, 2024

The market is a weighing machine in the long run, meaning these bargain stocks will deliver impressive forward returns.

Via InvestorPlace

Earnings Scheduled For February 28, 2024 ↗

February 28, 2024

Companies Reporting Before The Bell • ICL Group (NYSE:ICL) is likely to report quarterly earnings at $0.08 per share on revenue of $1.69 billion.

Via Benzinga

5 Value Stocks In The Healthcare Sector ↗

February 26, 2024

Via Benzinga

The Terrible Ten ↗

February 23, 2024

Most of the aforementioned group of quotable experts expect some mean reversion for the top stocks in the S&P 500 and counsel avoiding market cap weighting in favor of equal weighting.

Via Talk Markets

Topics Stocks

The Terrible Ten ↗

February 12, 2024

Many strategists recommend equal weighting over cap-weighting, claiming that over time, equal weighting always outperforms.

Via Talk Markets

These 9 Stocks Are Running To Start 2024 ↗

January 14, 2024

The S&P 500 is up just 0.2% in 2024. These stocks are off to a strong start.

Via Investor's Business Daily

Topics Stocks

Regeneron Pharma's Pipeline Makes This Analyst Turn Bullish ↗

January 12, 2024

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) won a lawsuit last month against Viatris Inc (NASDAQ: VTRS)

Via Benzinga

Topics Lawsuit

< Previous 1 2 3 4 5 6 7 8 9

...

14 15 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.